p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations

American Journal of Surgical Pathology

Volumn 28, Issue 9, 2004, Pages 1177-1183

  Shih, Ie Ming ^a   Kurman, Robert J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

p63; Trophoblast; Tumor

Indexed keywords

CYTOKERATIN 18; HLA G ANTIGEN; HUMAN PLACENTA LACTOGEN; KI 67 ANTIGEN; PROTEIN P53; PROTEIN P63;

ALGORITHM; ARTICLE; CARCINOGENICITY; CELL POPULATION; CELL SUBPOPULATION; CHORION; CONTROLLED STUDY; EPITHELIOID CELL; GENE; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; P63 GENE; PLACENTA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TROPHOBLAST; TROPHOBLASTIC TUMOR;

ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; PREGNANCY; TROPHOBLASTIC TUMOR, PLACENTAL SITE; TROPHOBLASTS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 4344567359     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000130325.66448.a1     Document Type: Article

References (25)

1. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002;8:494-501.
2. Geddert H, Kiel S, Heep HJ, Gabbert HE, et al. The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. Hum Pathol. 2003;34:850-856.
3. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA. 2000;97:5462-5467.
4. Kurita T, Cunha GR. Roles of p63 in differentiation of Mullerian duct epithelial cells. Ann NY Acad Sci. 2001;948:9-12.
5. Kurman RJ, Young RH, Norris HJ, et al. Immunocytochemical localization of placental lactogen and chorionic gonadotropin in the normal placenta and trophoblastic tumors, with emphasis on intermediate trophoblast and the placental site trophoblastic tumor. Int J Gynecol Pathol. 1984;3:101-121.
6. Little NA, Jochemsen AG. p63. Int J Biochem Cell Biol. 2002;34:6-9.
7. McMaster MT, Librach CL, Zhou Y, et al. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol. 1995; 154:3771-3778.
8. Patturajan M, Nomoto S, Sommer M, et al. DeltaNp63 induces betacatenin nuclear accumulation and signaling. Cancer Cell. 2002;1:369-379.
9. Senoo M, Matsumura Y, Habu S. TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. Oncogene. 2002;21:2455-2465.
10. Shih IM, Kurman RJ. Expression of melanoma cell adhesion molecule in intermediate trophoblast. Lab Invest. 1996;75:377-388.
11. Shih IM, Kurman RJ. Ki-67 labeling index in the differential diagnosis of exaggerated placental site, placental site trophoblastic tumor, and choriocarcinoma: a double immunohistochemical staining technique using Ki-67 and Mel-CAM antibodies. Hum Pathol. 1998;29:27-33.
12. Shih IM, Seidman JD, Kurman RJ. Placental site nodule and characterization of distinctive types of intermediate trophoblast. Hum Pathol. 1999;30:687-694.
13. Shih IM, Kurman RJ. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol. 2001;20:31-47.
14. Shih I-M, Kurman RJ. Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. Am J Surg Pathol. 1998;22:1393-1403.
15. Shih I-M, Kurman RJ. Molecular basis of gestational trophoblastic diseases. Curr Mol Med. 2002;2:1-12.
16. Shih I-M, Mazur MT, Kurman RJ. Gestational trophoblastic disease. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract, 5th ed. New York: Springer-Verlag, 2002:1193-1247.
17. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000;157:1769-1775.
18. Singer G, Kurman RJ, McMaster M, et al. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol. 2002;26:914-920.
19. Singer G, Rebmann V, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res. 2003;9:4460-4464.
20. Urist MJ, Di Como CJ, Lu ML, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol. 2002;161:1199-1206.
21. Westfall MD, Mays DJ, Sniezek JC, et al. The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol. 2003;23:2264-2276.
22. Wu G, Nomoto S, Hoque MO, et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res. 2003;63:2351-2357.
23. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305-316.
24. Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Natl Rev Mol Cell Biol. 2000;1:199-207.
25. Yang A, Kaghad M, Caput D, et al. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 2002;18:90-95.